Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Sarasota's Roskamp Institute Announces Positive Safety Data in Human Clinical Study for Alzheimer's Disease
April 10th, 2007
The Roskamp Institute announced that it has received positive preliminary results in its major clinical study that is testing a promising new drug application for the treatment of Alzheimer's disease. The clinical study, which was first announced in September, is the first human clinical study conducted by a Florida-based research institute as a result of its own original research. The announcement also highlighted achievements with the same drug in studies in Japan. The drug, Nilvadipine, has not shown any major side effects in Alzheimer's disease patients during the initial six months of the study that is being conducted in partnership with the Trinity College...
Source: Drug Law Weekly (2007-04-10)
|
